侵袭性真菌感染的诊断与治疗:未来展望
本文综述了侵袭性真菌感染诊断与治疗领域的未来发展方向。诊断方面,免疫色谱技术推动了隐球菌脑膜炎和侵袭性曲霉病的侧向层析设备开发,分子工具如T2Candida和曲霉邻近连接 assay 有助于快速诊断;影像学上CT仍是基石,MRI T2加权序列敏感性和特异性接近CT。治疗方面,两种新机制抗真菌药处于2期研究,一种处于1期,有望满足未被满足的临床需求。
要点
- 侧向层析设备可快速诊断隐球菌脑膜炎和侵袭性曲霉病
- T2Candida等核酸扩增技术有助于真菌病原体检测
- 两种新机制抗真菌药处于2期研究,一种处于1期
核心结论
- 改进的诊疗标准依赖于新实验室诊断、影像学方法及新抗真菌化合物的开发。
研究设计与样本
- 综述,检索范围未明确报告。
主要发现
- 免疫色谱技术已开发出用于隐球菌脑膜炎和侵袭性曲霉病诊断的侧向层析设备。
- 类似设备正在开发用于组织胞浆菌病检测,满足速度(约15分钟检测时间)和易用性要求。
- T2Candida等新核酸扩增技术有助于真菌病原体检测。
- 曲霉邻近连接 assay 已开发用于侵袭性曲霉病的快速床旁诊断。
- MRI T2加权 turbo-spin-echo 序列诊断侵袭性肺曲霉病的敏感性和特异性接近CT。
关键数值与推荐
- 目前有两种新机制抗真菌药处于2期研究用于系统性侵袭性真菌病,一种处于1期。
- 新抗真菌药提供口服和静脉制剂,部分药物药物相互作用潜力降低。
- 新作用机制使这些药物不易受念珠菌或曲霉常见耐药机制影响。
临床怎么用
- 侧向层析设备可用于隐球菌脑膜炎和侵袭性曲霉病的快速诊断。
- T2Candida等分子工具可辅助真菌病原体检测。
- MRI T2加权序列可作为避免辐射暴露的侵袭性肺曲霉病诊断选择。
局限性
- 分子工具检测真菌病原体的演变缓慢。
- 可能需要修改现有抗真菌药敏试验技术以纳入新化合物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Improved standards of care depend on the development of new laboratory diagnostic and imaging procedures and the development of new antifungal compounds. Immunochromatography technologies have led to the development of lateral flow devices for the diagnosis of cryptococcal meningitis and invasive aspergillosis (IA). Similar devices are being developed for the detection of histoplasmosis that meet the requirements for speed (∼15 min assay time) and ease of use for point-of-care diagnostics. The evolution of molecular tools for the detection of fungal pathogens has been slow but the introduction of new nucleic acid amplification techniques appears to be helpful, for example T2Candida. An Aspergillus proximity ligation assay has been developed for a rapid near-patient bedside diagnosis of IA. CT remains the cornerstone for radiological diagnosis of invasive pulmonary fungal infections. MRI of the lungs may be performed to avoid radiation exposure. MRI with T2-weighted turbo-spin-echo sequences exhibits sensitivity and specificity approaching that of CT for the diagnosis of invasive pulmonary aspergillosis. The final part of this review looks at new approaches to drug discovery that have yielded new classes with novel mechanisms of action. There are currently two new classes of antifungal drugs in Phase 2 study for systemic invasive fungal disease and one in Phase 1. These new antifungal drugs show promise in meeting unmet needs with oral and intravenous formulations available and some with decreased potential for drug-drug interactions. Novel mechanisms of action mean these agents are not susceptible to the common resistance mechanisms seen in Candida or Aspergillus. Modification of existing antifungal susceptibility testing techniques may be required to incorporate these new compounds.
引用
- Sanguinetti M, Posteraro B, Beigelman-Aubry C, et al. Diagnosis and treatment of invasive fungal infections: looking ahead. J Antimicrob Chemother. 2019. PMID: 31222314. doi:10.1093/jac/dkz041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。